236 completed, 28 unknown, 27 terminated, 10 withdrawn. 97 Phase 4, 96 Phase 3, 50 Phase 2, 29 Not applicable, 27 Phase 1.
Follow Sitagliptin: new trials by email Literature Review of Sitagliptin trials Research Report on Sitagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma Sitagliptin, Bevacizumab - Glioma, Glioblastoma | Phase 1 | Recruiting | Kailin Yang, MD, PhD | 45 | 2026-06-11 | 2026-06-17 |
| Sitagliptin With Pembro in RCC and Melanoma Sitagliptin, Pembrolizumab - Advanced Renal Cell Carcinoma, Advanced Melanoma | Phase 1 | Recruiting | Fernando Maciel Barbosa | 64 | 2026-05-14 | 2026-07-30 |
| A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. ABBV-722, Midazolam, Metformin - Healthy Volunteers | Phase 1 | Completed | AbbVie | 12 | 2026-04-30 | 2026-08-20 |
| A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Sitagliptin - Glioblastoma, Brain Tumor | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 48 | 2026-03-16 | 2026-08-06 |
| Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. Dulaglutide, Sitagliptin - Type 2 Diabetes | Completed | Brigham and Women's Hospital | 300000 | 2026-02-03 | 2026-07-10 | |
| INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) Dulaglutide, Semaglutide, Tirzepatide - Type 2 Diabetes, Overweight | Completed | Brigham and Women's Hospital | 60000 | 2026-01-27 | 2026-07-09 | |
| Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) Oral semaglutide, Sitagliptin - Type 2 Diabetes, Heart Failure | Completed | Brigham and Women's Hospital | 25664 | 2026-01-24 | 2026-09-21 | |
| Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2 | Phase 4 | Completed | Fundación para la Investigación del Hospital Clínico de Valencia | 92 | 2025-05-26 | 2026-09-04 |
| Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes Tirzepatide, Pioglitazone, Sitagliptin - Type 2 Diabetes (Adult Onset) | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 256 | 2024-11-07 | 2026-03-10 |
| Emulation of the SOUL Diabetes Trial in Healthcare Claims Oral semaglutide, Sitagliptin - Diabetes Mellitus, Type 2 | Completed | Brigham and Women's Hospital | 43650 | 2024-10-24 | 2025-05-25 | |
| Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data Empagliflozin, Sitagliptin - Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure | Completed | Brigham and Women's Hospital | 39614 | 2024-10-13 | 2026-07-09 | |
| Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data Empagliflozin, Sitagliptin - Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure | Completed | Brigham and Women's Hospital | 23955 | 2024-10-13 | 2026-07-10 | |
| Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk Tirzepatide, Dulaglutide, Semaglutide - Type 2 Diabetes, Overweight | Completed | Brigham and Women's Hospital | 887132 | 2024-10-01 | 2025-10-15 | |
| Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS Sitagliptin, BeiDouGen, Sitagliptin+BeiDouGen - Polycystic Ovarian Syndrome | Not applicable | Recruiting | Peking University Third Hospital | 300 | 2024-08-21 | 2024-09-19 |
| Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment Canagliflozin group, Sitagliptin, Acarbose - Type 2 Diabetes Mellitus, Cognitive Impairment | Phase 4 | Recruiting | Fudan University | 60 | 2024-08-19 | 2026-07-17 |
| Anti-Diabetic Medications to Fight PD and LBD Sitagliptin, Dapagliflozin, Placebo - Lewy Body Dementia, Parkinson Disease | Phase 4 | Completed | Mayo Clinic | 18 | 2024-05-07 | 2026-01-28 |
| To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis Metformin, Sitagliptin, Dapagliflozin - Compensated Cirrhosis, Decompensated Cirrhosis | Not applicable | Unknown | Institute of Liver and Biliary Sciences, India | 240 | 2023-12-20 | 2023-12-08 |
| High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD Sitagliptin, Bortezomib, Cyclophosphamide - Bone Marrow Transplant Complications, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Indiana University | 2023-11-01 | 2024-04-29 |
Showing 20 of 311. Sign in to see all of them.
Diabetes Mellitus, Type 2 (211) · Diabetes Mellitus (68) · Diabetes Mellitus, Type 1 (14) · Hyperglycemia (8) · Insulin Resistance (8) · Glucose Intolerance (7) · Inflammation (6) · Non-alcoholic Fatty Liver Disease (5) · Atherosclerosis (4) · Cystic Fibrosis (4) · Heart Failure (4) · Obesity (4) · Prediabetic State (4) · Cardiovascular Diseases (3) · Hypertension (3)
Merck Sharp & Dohme LLC (39) · Novo Nordisk A/S (13) · AstraZeneca (12) · Brigham and Women's Hospital (10) · Novartis Pharmaceuticals (7) · Boehringer Ingelheim (6) · Emory University (6) · GlaxoSmithKline (6) · Eli Lilly and Company (5) · Sanofi (5) · Vanderbilt University (5) · Lund University (4) · Takeda (4) · University Hospital, Gentofte, Copenhagen (4) · Canadian Network for Observational Drug Effect Studies, CNODES (3)
United States (128) · Germany (31) · South Korea (29) · Canada (26) · India (24) · China (20) · Mexico (20) · Spain (18) · United Kingdom (17) · Poland (16) · France (15) · Japan (15) · Romania (15) · Russia (15) · Argentina (14)
Shirley Wang, PhD, ScM (10) · Guillermo Umpierrez, MD (4) · Pierre Ernst, MD, MSc (3) · Guang Ning, MD. PHD (2)
PMID 32998732, PMID 24517339, PMID 24742013, PMID 24786834, PMID 24918789, PMID 25329038, PMID 25813214, PMID 26121561, PMID 26373629, PMID 26580237, PMID 27600862, PMID 27977934, PMID 28197834, PMID 28241822, PMID 28327140, PMID 31797522, PMID 31903692, PMID 32306296, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 38770818, PMID 23522121, PMID 23748506, PMID 23748507, PMID 24432999, PMID 24699248, PMID 26579834, PMID 30880443, PMID 32267058, PMID 32700393, PMID 33660198, PMID 34033212, PMID 35373893, PMID 35472672, PMID 37178435, PMID 39963952, PMID 10752702, PMID 11495032, PMID 16033281, PMID 16400329, PMID 17622601, PMID 18539916, PMID 18539917, PMID 18784090, PMID 18786299, PMID 19073764, PMID 19114612, PMID 19336687
2008 (6), 2015 (6), 2014 (3), K23HL119602 (2), 2009 (1), 2018 (1), 2019 (1), 2025 (1), R01DK097554 (1), R01HL112669 (1), R03DK084089 (1), U01DK098246 (1), U54RR014616 (1), UM1AI068636 (1)